

Sample Patient

Date of Birth: 01/01/2000

Gender: U

Specimen ID: 3333333333

Control ID: L88888888

Account Number:
Status: Final

Specimen Details:
Collection Date:
Patient ID: 0

Physician Details:
Provider: FIELDER

Report Date:
Alt. Patient ID:
NPI Number:
Ordered Items: C-Reactive Protein, Cardiac; CBC With Differential/Platelet; Comp. Metabolic Panel (14); Hgb A1c with eAG Estimation; Homocyst(e)ine; Lipid Panel With LDL/HDL Ratio; NMR LipoProfile+IR Markers; NMR LipoProfile+Lipids+Graph; Thyroid Panel With TSH

Test Name	Result	LabCorp Reference Range	Result	Walsh/Pfeiffer Functional Range	Flag	Units	Lab
C-Reactive Protein, Cardiac							
• C-Reactive Protein, Cardiac	4.99	0.00-3.00			High	mg/L	02
<i>Relative Risk for Future Cardiovascular Event</i>							
<i>Low <1.00</i>							
<i>Average 1.00 - 3.00</i>							
<i>High >3.00</i>							
CBC With Differential/Platelet							
• WBC	6.6	3.4-10.8				x10E3/uL	02
• RBC	5.78	4.14-5.80				x10E6/uL	02
• Hemoglobin	17.4	13.0-17.7				g/dL	02
• Hematocrit	50.7	37.5-51.0				%	02
• MCV	88	79-97				fL	02
• MCH	30.1	26.6-33.0				pg	02
• MCHC	34.3	31.5-35.7				g/dL	02
• RDW	12.6	11.6-15.4				%	02
• Platelets	228	150-450				x10E3/uL	02
• Neutrophils	71	Not Estab.				%	02
• Lymphs	18	Not Estab.				%	02
• Monocytes	6	Not Estab.				%	02
• Eos	3	Not Estab.				%	02
• Basos	1	Not Estab.				%	02
• Neutrophils (Absolute)	4.6	1.4-7.0				x10E3/uL	02
• Lymphs (Absolute)	1.2	0.7-3.1				x10E3/uL	02
• Monocytes(Absolute)	0.4	0.1-0.9				x10E3/uL	02
• Eos (Absolute)	0.2	0.0-0.4				x10E3/uL	02
• Baso (Absolute)	0	0.0-0.2				x10E3/uL	02
• Immature Granulocytes	1	Not Estab.				%	02
• Immature Grans (Abs)	0.1	0.0-0.1				x10E3/uL	02

Comp. Metabolic Panel (14)

Test Name	Result	LabCorp Reference Range	Result	Walsh/Pfeiffer Functional Range	Flag	Units	Lab
• Glucose	112	65-99			High	mg/dL	02
• BUN	15	6-24				mg/dL	02
• Creatinine	0.83	0.76-1.27				mg/dL	02
• eGFR	103	>59				mL/min/1.73	02
• BUN/Creatinine Ratio	18	9-20					02
• Sodium	142	134-144				mmol/L	02
• Potassium	4.8	3.5-5.2				mmol/L	02
• Chloride	102	96-106				mmol/L	02
• Carbon Dioxide, Total	25	20-29				mmol/L	02
• Calcium	10	8.7-10.2				mg/dL	02
• Protein, Total	6.7	6.0-8.5				g/dL	02
• Albumin	4.4	3.8-4.9				g/dL	02
• Globulin, Total	2.3	1.5-4.5				g/dL	02
• A/G Ratio	1.9	1.2-2.2					02
• Bilirubin, Total	0.5	0.0-1.2				mg/dL	02
• Alkaline Phosphatase	94	44-121				IU/L	02
• AST (SGOT)	23	0-40				IU/L	02
• ALT (SGPT)	31	0-44				IU/L	02

Hgb A1c with eAG Estimation

• Hemoglobin A1c	5.4	4.8-5.6				%	02
------------------	-----	---------	--	--	--	---	----

Prediabetes: 5.7 - 6.4
Diabetes: >6.4
Glycemic control for adults with diabetes: <7.0

• Estim. Avg Glu (eAG)	108					mg/dL	02
------------------------	-----	--	--	--	--	-------	----

Homocyst(e)ine

• Homocyst(e)ine	11.4	0.0-14.5				umol/L	02
------------------	------	----------	--	--	--	--------	----

Lipid Panel With LDL/HDL Ratio

• Cholesterol, Total	265	100-199			High	mg/dL	02
• Triglycerides	116	0-149				mg/dL	02
• HDL Cholesterol	53	>39				mg/dL	02
• VLDL Cholesterol Cal	21	5-40				mg/dL	02
• LDL Chol Calc (NIH)	191	0-99			High	mg/dL	02
• LDL/HDL Ratio	3.6	0.0-3.6				ratio	02

LDL/HDL Ratio
Men Women
1/2 Avg.Risk 1.0 1.5
Avg.Risk 3.6 3.2
2X Avg.Risk 6.2 5.0
3X Avg.Risk 8.0 6.1

NMR LipoProfile+IR Markers

• LDL-P	2323	<1000			High	nmol/L	01
---------	------	-------	--	--	------	--------	----

Test Name	Result	LabCorp Reference Range	Result	Walsh/Pfeiffer Functional Range	Flag	Units	Lab
Low < 1000 Moderate 1000 - 1299 Borderline-High 1300 - 1599 High 1600 - 2000 Very High > 2000							
• HDL-P (Total)	35.8	>=30.5				umol/L	01
• Small LDL-P	795	<=527			High	nmol/L	01
• LDL Size	21.5	>20.5				nm	01
----- ** INTERPRETATIVE INFORMATION** PARTICLE CONCENTRATION AND SIZE <--Lower CVD Risk Higher CVD Risk--> LDL AND HDL PARTICLES Percentile in Reference Population HDL-P (total) High 75th 50th 25th Low >34.9 34.9 30.5 26.7 <26.7 . Small LDL-P Low 25th 50th 75th High <117 117 527 839 >839 . LDL Size <-Large (Pattern A)-> <-Small (Pattern B)-> 23.0 20.6 20.5 19.0 ----- Small LDL-P and LDL Size are associated with CVD risk, but not after LDL-P is taken into account.							
• Large VLDL-P	3.5	<=2.7			High	nmol/L	01
• Small LDL-P	795	<=527			High	nmol/L	01
• Large HDL-P	2	>=4.8			Low	umol/L	01
• VLDL Size	48.2	<=46.6			High	nm	01
• LDL Size	21.5	>=20.8				nm	01
• HDL Size	8.3	>=9.2			Low	nm	01
• LP-IR Score	65	<=45			High		01

Test Name	Result	LabCorp Reference Range	Result	Walsh/Pfeiffer Functional Range	Flag	Units	Lab
INSULIN RESISTANCE / DIABETES RISK MARKERS							
<--Insulin Sensitive Insulin Resistant-->							
Percentile in Reference Population							
Large VLDL-P Low 25th 50th 75th High							
<0.9 0.9 2.7 6.9 >6.9							
.							
Small LDL-P Low 25th 50th 75th High							
<117 117 527 839 >839							
.							
Large HDL-P High 75th 50th 25th Low							
>7.3 7.3 4.8 3.1 <3.1							
.							
VLDL Size Small 25th 50th 75th Large							
<42.4 42.4 46.6 52.5 >52.5							
.							
LDL Size Large 75th 50th 25th Small							
>21.2 21.2 20.8 20.4 <20.4							
.							
HDL Size Large 75th 50th 25th Small							
>9.6 9.6 9.2 8.9 <8.9							
Insulin Resistance Score							
LP-IR SCORE Low 25th 50th 75th High							
<27 27 45 63 >63							
.							
LP-IR Score is inaccurate if patient is non-fasting.							
.							
The LP-IR score is a laboratory developed index that has been associated with insulin resistance and diabetes risk and should be used as one component of a physician's clinical assessment.							

NMR LipoProfile+Lipids+Graph

• LDL-C (NIH Calc)	190	0-99			High	mg/dL	01
.							
Optimal < 100							
Above optimal 100 - 129							
Borderline 130 - 159							
High 160 - 189							
Very high > 189							
.							
• HDL-C	54	>39				mg/dL	01
• Triglycerides	119	0-149				mg/dL	01
• Cholesterol, Total	265	100-199			High	mg/dL	01
• LP-IR Score	65	<=45			High		01
INSULIN RESISTANCE MARKER							
<--Insulin Sensitive Insulin Resistant-->							
Percentile in Reference Population							
Insulin Resistance Score							
LP-IR Score Low 25th 50th 75th High							
<27 27 45 63 >63							
LP-IR Score is inaccurate if patient is non-fasting.							
.							
The LP-IR score is a laboratory developed index that has been associated with insulin resistance and diabetes risk and should be used as one component of a physician's clinical assessment.							
• PDF	.						01

Thyroid Panel With TSH

• TSH	1.7	0.450-4.500				uIU/mL	02
• Thyroxine (T4)	9.3	4.5-12.0				ug/dL	02
• T3 Uptake	26	24-39				%	02

Test Name	Result	LabCorp Reference Range	Result	Walsh/Pfeiffer Functional Range	Flag	Units	Lab
• Free Thyroxine Index	2.4	1.2-4.9					02

DHA Laboratory

411 E Business Center Dr #107, Mt Prospect, IL 60056

Email: info@dhalab.com | Phone: 847-222-9546 | Fax: 847-222-9547

***NOTE:** The reference range(s) listed on this report are different than functional ranges. When determining biochemical imbalances based on the Carl Pfeiffer M.D./William Walsh Ph.D. model; Optimal functional ranges represent a range within a reference range that can position a patient within biochemical classes: (1) elevated histamine (2) low histamine (3) excess copper (4) zinc deficiency. Optimal functional ranges for patients may vary based on diagnosis, clinical features and response to treatment.

Laboratory Director: Judith Bowman, MD | CLIA #: 14D0995837

Reference Testing Facilities:

Lab	Lab Name and Address	Lab Phone Numbers	Lab Medical Director
01	Labcorp Burlington, 1447 York Court, Burlington NC 272153361	8007624344	Nagendra, Sanjai MD
02	Labcorp Dublin, 6370 Wilcox Road, Dublin OH 430161269	8002827300	Ricchiuti, Vincent PhD

Specimen Number		Patient ID		Account Number	Account Phone	Account Fax
Patient Last Name		Patient First Name		Account Address		
Age	Date of Birth	Sex	Fasting			
Control Number		NPI				
Date Collected	Date Entered	Date and Time Reported		Physician ID & Name FIELDER		Page Number 1 of 2

❖ **NMR LipoProfile® test**

Reference Interval¹


	Percentile ¹	20th	50th	80th	95th	
	Low	Moderate	Borderline High	High	Very High	
LDL-P (LDL Particle Number)	2323	< 1000	1000 - 1299	1300 - 1599	1600 - 2000	> 2000

1. Reference population (5,362 men and women) not on lipid medication enrolled in the Multi-Ethnic Study of Atherosclerosis (MESA). Mora, et al. Atherosclerosis 2007.

❖ **Lipids**

	mg/dL	Optimal	Near or Above Optimal	Borderline High	High	Very High
LDL-C (calculated)	190	< 100	100 - 129	130 - 159	160 - 189	≥ 190
HDL-C	54	Triglycerides		119	Total Cholesterol	
	Desirable ≥ 40			Desirable < 150	Desirable < 200	

Historical Reporting



❖ This test was developed and its performance characteristics determined by LabCorp. It has not been cleared or approved by the US Food and Drug Administration.



Issued or Pending PATENTS

The NMR LipoProfile® test may be covered by one or more issued or pending patents, including U.S. Patent Nos. 6,518,069; 6,576,471; 6,653,140; and 7,243,030

CLIA Number 34D0655059

Specimen Number		Patient ID		Account Number	Account Phone	Account Fax
Patient Last Name		Patient First Name		Account Address		
Age	Date of Birth	Sex	Fasting			
Control Number		NPI				
Date Collected	Date Entered	Date and Time Reported		Physician ID & Name FIELDER		Page Number 2 of 2

PARTICLE CONCENTRATION AND SIZE



❖ This test was developed and its performance characteristics determined by LabCorp. It has not been cleared or approved by the US Food and Drug Administration.

① LipoScience reference population comprises 4,588 men and women without known CVD or diabetes and not on lipid medication.

② Shalurova I et al., Metab Syndr Relat Disord 2014; 12:422-9.

③ Mackey RH et al., Diab Care 2015; 38:628-36.